SALT LAKE CITY, UTAH / ACCESS Newswire / February 6, 2025 /CenExel, a leading network of clinical research sites, proudly ...
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...
The FDA has approved Journavx, a new non-opioid painkiller designed to treat moderate to severe acute pain. Unlike opioids, ...
For the first time in decades, a new class of painkiller has been approved by the US Food and Drug Administration (FDA).
The Food and Drug Administration (FDA) has approved Journavxâ„¢ (suzetrigine) for the treatment of moderate to severe acute pain in adults.
Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.
proudly congratulates and announces its role in supporting Vertex Pharmaceuticals' clinical studies that led to the FDA approval of JOURNAVXâ„¢ (suzetrigine), the first-in-class, non-opioid oral ...
The US Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or overdose linked to drugs like Vicodin and OxyContin.